inclusion criteria: - a man or a woman, 18 years or older - willing and able to provide informed consent, or with a legal representative who can provide informed consent with participant's assent - has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by an approved diagnostic test before randomization - currently hospitalized - documented increase in serum creatinine of 0.3 mg/dl or 50%-99% over baseline (baseline either based on admission serum creatinine or known pre-admission baseline, defined as most recent previous measurement) - participant or legal representative has read and signed the informed consent form (icf) after the nature of the study has been fully explained - is willing and able to provide authorization for the use and disclosure of personal health information in accordance with health insurance portability and accountability act (hipaa) - patients who are receiving remdesivir as a part of their clinical care or are in clinical trials of remdesivir or other antiviral drugs may be allowed if they meet other eligibility criteria - patients, who are participating in observational studies or studies of nonpharmacological interventions, will be allowed to participate - not be pregnant and not planning to become pregnant over the next 6 months

inclusion criteria: - a man or a woman, 18 years or older - willing and able to provide informed consent, or with a legal representative who can provide informed consent with participant's assent - has severe acute respiratory syndrome coronavirus (sars-cov)-2 infection confirmed by an approved diagnostic test before randomization - currently hospitalized - documented increase in serum creatinine of 0.3 mg/dl or 50%-99% over baseline (baseline either based on admission serum creatinine or known pre-admission baseline, defined as most recent previous measurement) - participant or legal representative has read and signed the informed consent form (icf) after the nature of the study has been fully explained - is willing and able to provide authorization for the use and disclosure of personal health information in accordance with health insurance portability and accountability act (hipaa) - patients who are receiving remdesivir as a part of their clinical care or are in clinical trials of remdesivir or other antiviral drugs may be allowed if they meet other eligibility criteria - patients, who are participating in observational studies or studies of nonpharmacological interventions, will be allowed to participate - not be pregnant and not planning to become pregnant over the next 6 months